Starting & switching disease-modifying therapies (DMTs) – EAN 2020
EAN Congress 2020 Dr Wallace Brownlee and Dr Kate Petheram discussed their highlights from the EAN Conference around the topic of starting and switching disease-modifying therapies (DMTs) in multiple sclerosis (MS). Switching to ocrelizumab after failure of another DMT (1.08) Two separate studies were presented which looked at patients treated effectively with ocrelizumab after having […]
Progressive MS – EAN 2020
EAN Congress 2020 Dr Wallace Brownlee and Dr Kate Petheram discussed highlights from the EAN Conference regarding progressive MS. Unsuccessful research in progressive MS (0.36) Kate noted that often this area of research can be rather pessimistic; in this case there were two negative studies reported on at the conference and one positive which she […]
Webinar: MS – the future
Please note that all session and slide content are the views of the Speakers, not the MS Academy. The content of the recording is the speaker’s personal opinion at the time of recording. Due to the everchanging situation, advice given at the time of recording is subject to change. CPD acceditation This webinar has been approved […]
Are the ‘Forgotten Many’ forgotten again? NICE rejects Novartis’ Mayzent for SPMS
Before we, as the MS Academy, respond to NICE it is important we do a short survey to find out what the situation is on the ground and see if there is any consensus in our practice. We would appreciate it if you spend 2 to 4 minutes completing the following survey. Survey The National […]
Paediatric MS and NMO – EAN 2020
EAN Congress 2020 Rachel Dorsey-Campbell and Dr Wallace Brownlee discussed some of their highlights from the EAN conference regarding Neuromyelitis Optica (NMO) and Paediatric MS. Neuromyelitis Optica (NMO) and recent advances (0.32) Rachel noted a poster looking at the safety data for satralizumab. It was very positive that there were no stand-out side effects; headache […]
Depression and MS: Diagnosing and treating: Anthony Feinstein, MD PhD
2020 CMSC Virtual Annual Meeting Questions answered 0:25 – Why is it important to identify and manage depression in PwMS? 1:29 – It can be difficult to know if patients are depressed or if some of the symptoms are due to their MS? 2:06 – If a patient is low in mood or exhibiting signs […]
The long term implications of COVID-19 are becoming apparent
We have become increasingly aware, over the past few months, that the symptoms of COVID-19 are wider ranging than initially thought. A recent article in Reuters has highlighted the full extent of this, and called into question whether we are prepared, as a society, for the rehabilitative process that will be needed by many who […]
CNS Immune Response in Progressive MS: Future Challenges in the Covid-19 Era: Peter A. Calebresi, MD
2020 CMSC Virtual Annual Meeting Write-up by Denisse Bongol Aims of the session Peter Calebresi shared a series of learning objectives from the session, which were to: To recognise the putative mechanisms underlying disease progression in multiple sclerosis (MS), To describe the oligodendrocyte precursor cells and the potential for endogenous remyelination in MS To incorporate […]
The Science, Art and Practice of Behavioural Medicine in MS: Amy B Sullivan PsyD ABPP
2020 CMSC Virtual Annual Meeting Write-up by Denisse Bongol Aims of the session Amy Sullivan shared a series of learning objectives from the session, which were to: Examine the cost of chronic diseases and mental health issues in the general population, Improve ability to assess and understand the path of the person with MS, Describe […]
DMT safety issues – EAN 2020
EAN Congress 2020 Joela Mathews and Rachel Dorsey-Campbell discussed some of their highlights from the EAN 2020 focussing on drug safety. Alemtuzumab safety (0.39) Rachel outlined a poster session on the safety of alemtuzumab over a nine year period in patients with non-MS autoimmunity. It investigated the relationship between pre-existing autoimmunity and a higher risk […]